Analyst Price Target is $8.33
▲ +88.54% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Gain Therapeutics in the last 3 months. The average price target is $8.33, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 88.54% upside from the last price of $4.42.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Gain Therapeutics. This Buy consensus rating has held steady for over two years.
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.